Lengthy drug approval procedures can result in drug trials of 13-15 years. However, with patents only lasting 20 years and exclusivity for 7 years, limited time exists for a pharmaceutical company to re-gain their investment. It is estimated that reducing a development programme by 18 months can increase the value of a drug by £150 million and will provide quicker therapeutic benefits to patients.